Serono of Switzerland has launched a new needle-free formulation of itshuman growth hormone product Serostim (somatropin for injection) in the USA, marketed for wasting in patients suffering from HIV/AIDS. The new product, called SeroJet, is the first needle-free hGH product to be made available in the USA and will be offered at no additional cost to Serostim patients. Serono is hoping that the launch of SeroJet will go some way towards offsetting a decline in Serostim sales, which were down 8.5% to $125.3 million in 2001 and dropped 20.3% in the fourth quarter to $27 million, compared to the same period of 2000. The decline reflects a tightening in reimbursement for the drug and matters are unlikely to improve in 2002, said Serono.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze